Search results for: Determining Value
Filter search results
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment
1 April 2019
…value assessment in delivering value for money. This is inconsistent with both existing WHA policy on HTA and the reality that more and more payers in WHO Member States are…
Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?
1 May 2012
…practice and expected production cost, rather than assessments of value. The paper discusses how a value based pricing (VBP) framework for efficient use and pricing of medicines also might be…
Using MCDA to Assess the Value of Treatments for Rare Diseases
5 December 2013
…for rare disease may be effectively valued using an innovative approach — multi-criteria decision analysis (MCDA) — that can include all relevant stakeholders, including patients’ groups. Assessing value for treatments…
Understanding societal preferences for priority by disease severity in England & Wales
14 November 2024
…found a fairly rapid increase in the relative value of treating more severe patient groups, even at relatively moderate levels of shortfall, and that relative value plateaus at about 1.7…
NICE Recommendation Highlights Role of Social Value Judgements
9 August 2018
This blog post discusses the role of social value judgements in NICE technology appraisals, focusing on the recent appraisal of dinutuximab beta for high-risk neuroblastoma. The use of social value…
Should We ‘Drop Dead’ from Health State Valuation?
10 December 2020
…David Parkin, and Nancy Devlin argue the case for ‘Dropping Dead’ as the anchor for health state values. And the authors would like your feedback. By convention, the values developed…
Evidence on Valued Based Pricing and Reimbursement Schemes
30 September 2011
…medicines. Poster presented PPRI Conference 2011. Vienna. 29-30 September. Related OHE research: Operationalising Value Based Pricing, an OHE Research Paper. See also the posts on value-based pricing in this blog….
Establishing a Reasonable Price for an Orphan Drug
1 July 2018
…should be forgone in order to provide funding for treatments for rare conditions and, if so, how much. Rather, the authors’ approach is one way of determining the maximum allowable…
Report of the Office of Health Economics Commission on Competition in the NHS
1 January 2012
…Determining when and where competition is most likely to be effective is a challenge because health care consists of such a wide variety of very different services, delivered in dissimilar…